Remember hydroxychloroquine, the 65 year drug originally used to combat malaria that appeared to fight COVID-19 as well?
Remember how initial studies showed it had great promise, but then a couple of studies – one of which was debunked as fraudulent – showed it did not?
And remember how remdesivir – new, and enormously expensive to use – was then pushed (still is) as its far superior alternative?
With the above in mind, please read the beginning of Sharyl Attkisson’s article at justthenews.com:
The anti-malaria drug that President Trump touted as a possible treatment for coronavirus, hydroxychloroquine, successfully lowered the death rate among hospitalized COVID-19 patients in the most recent study of the drug.
The large-scale analysis, conducted by Henry Ford Health System, was published Thursday in the peer-reviewed International Journal of Infectious Diseases.
The study examined 2,541 patients who had been hospitalized in six hospitals between March 10 and May 2, 2020.
The article goes on to provide the specifics on how well hydroxychloroquine works…
…which leads to an interesting little comparative.
-Hydroxychloroquine, first introduced in the mid-1950’s. is long out of patent, and costs very little to produce, thus very little (about 60 cents a pill) for COVID-19 sufferers to purchase.
-By contrast, Remdesivir is new, and wildly expensive. Gilead Sciences, which holds the patent, is going to charge, believe it or not, $2,340 for a five-day treatment.
And, as we all know, President Trump, who is always in league with those rich-and-want-to-get-even-richer pigs, is heavily touting the Remdesivi…….
…..er, wait a minute. That’s not right. Trump has heavily touted, and continues to tout, the hydroxochloroquine – the stuff that costs next to nothing.
Is hydroxychloroquine an answer? Does it really help, at a minimal cost to COVID-19 sufferers? This latest study suggests the answer may be yes.
Let’s hope so.